JUPITER

Question 1

JUPITER Trial clinical question

Answer 1

In patients with normal LDL and elevated high-sensitivity CRP (HS-CRP), does rosuvastatin reduce the incidence of major CV events?

Question 2

JUPITER Trial bottom line

Answer 2

Among patients with normal LDL but elevated HS-CRP, rosuvastatin reduces the incidence of CV events.

Question 3

n and groups JUPITER trial

Answer 3

18,000, rosuvastatin or placebo

Question 4

in JUPITER patients were followed until

Answer 4

1st CV event

Question 5

JUPITER NNT @ 5 years

Answer 5

25

Question 6

JUPITER criticisms

Answer 6

1. truncated early, and thus quite possibly overestimating the effect
2. low ASA use and poorly controlled HTN
3. No asians- metabolize rosuvastatin differently
4. there was no clear indication that an elevated HS-CRP was required for rosuvastatin to confer a benefit, since individuals with HS-CRP <2 mg/L were not evaluated.

Question 7

JUPITER design

Answer 7

Multicenter, double blind, 17,802, intention to treat

Question 8

JUPITER primary outcome

Answer 8

Combined endpoint of first major CV event

Question 9

Jupiter Inclusion criteria

Answer 9

• Men >50 years, or -women >60 years
• LDL <130 mg/dL
• HS-CRP >2.0 mg/L
• Triglycerides <500 mg/dL
• No history of CV disease

Question 10

JUPITER outcome numbers

Answer 10

First major CV event (non-fatal MI, non-fatal stroke, hospitalization for UA, arterial revascularization procedure, or death from CV causes)
0.77 vs. 1.36 (HR 0.56; 95% CI 0.46-0.69)